Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.53 |
| ▸ | ANPEP | P15144 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17994239 | 0.93 | MME (0.49) | MMEANPEPCTSSCTSKCTSB | |
| SCHEMBL10119263 | 0.91 | CTSS (0.60) | MMEANPEPCTSSCTSKCTSB | |
| SCHEMBL14297648 | 0.91 | CTSS (0.60) | MMEANPEPCTSSCTSKCTSB | |
| SCHEMBL16305952 | 0.90 | L3MBTL1 (0.48) | MMEANPEPCTSSCTSKCTSB | |
| SCHEMBL16375203 | 0.88 | CTSL (0.53) | MMEANPEPCTSLACECPA1 | |
| SCHEMBL16375212 | 0.87 | PTPN1 (0.57) | MMEACECPA1ACE2 | |
| SCHEMBL16375204 | 0.87 | CTSS (0.50) | CTSSCTSKCTSBL3MBTL1PSMB5 | |
| SCHEMBL16305972 | 0.86 | L3MBTL1 (0.45) | MMEANPEPCTSSCTSKCTSB | |
| SCHEMBL16343523 | 0.86 | L3MBTL1 (0.45) | MMEANPEPCTSSCTSKCTSB | |
| SCHEMBL10118946 | 0.86 | CTSS (0.67) | MMEANPEPCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
| US-9598430-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-03-21 | — | — | US | disclosed |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-07-28 | — | — | US | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MME 796/4885ANPEP 305/4885CTSS 3233/4885 |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MME 796/4885ANPEP 305/4885CTSS 3233/4885 |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | MME 796/4885ANPEP 305/4885CTSS 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.